Skip to main content
Global
Global Fin Swe Nor Den Ger Cze Svk Pol Hun Nld Bel (nl) Bel (fr) USA
Log in
  • Aidian – Your aid in diagnostics
  • Products
  • About us
  • News
  • Antimicrobial resistance
  • Aidian Academy
  • Customer stories
  • Events
  • For distributors / Log in
Contact us Search
Logo
Contact us
  • Point of care
  • Microbiology
  • Molecular diagnostics
  • Hygiene monitoring
  • RIA / Collagens
  • Respiratory tract infections
  • Products available in the USA
Point of care
  • QuikRead go system
  • QuikRead 101
Read more
QuikRead go
  • QuikRead go Plus Instrument
  • QuikRead go Instrument
  • QuikRead go easy CRP
  • QuikRead go CRP
  • QuikRead go CRP+Hb
  • QuikRead go wrCRP
  • QuikRead go wrCRP+Hb
  • QuikRead go HbA1c
  • QuikRead go Strep A
  • QuikRead go iFOBT
  • QuikRead go accessories
QuikRead go
Microbiology
  • Uricult
  • Uricult Vet
  • Cultura M
Read more
Molecular diagnostics
  • SIBA
Read more
SIBA licensing and partnering opportunities
Read more
Hygiene monitoring
  • Easicult
  • Hygicult
  • Clean Card PRO
Read more
NEW! A comprehensive guide to monitoring surface hygiene now published
Read more
RIA / Collagens
  • UniQ
Read more
  • Our history
  • Board and management
  • Sustainability
  • Culture
  • Careers
  • Employee stories
  • Partnering and licensing
  • UN Global Compact Commitment | Aidian
  • News
  • Product news
  • AMR
  • Events
  • Stories from customers
  • COVID-19
  • About C-reactive protein (CRP)
  • AMR interview
  • CRP and lower respiratory tract infections
  • Educational materials
  • QuikRead go CRP products
  • Spreading of antibiotic resistant bacteria
  • Useful links
  • Generally
  • Product information
  • Courses
  • Documents and materials
  • Frequently asked questions
  • Sleeping hygiene: monitoring cleanliness of pillows and bedding
Logo
Contact us Close
  • Products
    • Point of care
      • QuikRead go system
      • QuikRead 101
    • Microbiology
      • Uricult
      • Uricult Vet
      • Cultura M
    • Molecular diagnostics
      • SIBA
    • Hygiene monitoring
      • Easicult
      • Hygicult
      • Clean Card PRO
    • RIA / Collagens
      • UniQ
    • Respiratory tract infections
    • Products available in the USA
  • About us
    • Our history
    • Board and management
    • Sustainability
    • Culture
    • Careers
    • Employee stories
    • Partnering and licensing
    • UN Global Compact Commitment | Aidian
  • News
    • News
    • Product news
    • AMR
    • Events
    • Stories from customers
    • COVID-19
  • Antimicrobial resistance
    • About C-reactive protein (CRP)
    • AMR interview
    • CRP and lower respiratory tract infections
    • Educational materials
    • QuikRead go CRP products
    • Spreading of antibiotic resistant bacteria
    • Useful links
  • Aidian Academy
    • Generally
    • Product information
    • Courses
    • Documents and materials
    • Frequently asked questions
  • Customer stories
    • Sleeping hygiene: monitoring cleanliness of pillows and bedding
  • Events
  • For distributors / Log in
Popular products
QuikRead go Plus Instrument

QuikRead go Plus Instrument

QuikRead go HbA1c

QuikRead go HbA1c

SIBA

SIBA

Latest news
View all

May 5 is World Hand Hygiene Day

May 5, 2025 | News, Product news

Meet us at EuroMedLab 2025!

April 29, 2025 | Events

Are you prepared for tick season?

April 9, 2025 | News, Product news

  • View all
  • No results found
  • Loading...
News

May 5 is World Hand Hygiene Day

May 5, 2025 | News, Product news

Meet us at EuroMedLab 2025!

April 29, 2025 | Events

Back to all news
September 8, 2021
News,
AMR,
COVID-19

Antimicrobial resistance has accelerated during COVID-19

In the past decade, antimicrobial resistance (AMR) has been pointed out as an emerging global health threat. Now there are concerns that COVID-19 may have accelerated AMR due to increased use of antibiotics, although there is no scientific evidence that antibiotics would benefit in the treatment of COVID-19. Also, the increased number of hospital stays and invasive procedures in intensive care units (ICU) increased the risk for secondary bacterial infections that may require antibiotic therapy1. In ICU, ventilator associated pneumonia is a relatively common secondary infection, but patients also have urinary tract and bloodstream infections.

Antibiotics are commonly used in COVID-19 without confirmed secondary bacterial infection

At the beginning of the pandemic, antibiotics were widely used and prescribed especially for hospitalized COVID-19 patients often without an appropriate diagnosis of bacterial co-infection. As an example, in a multi-hospital cohort study in the USA, 57% of the 1705 patients received early empiric antibiotic treatment, of which only 3.5% had bacterial infection2. Another example from the USA is a study with almost 5000 participants demonstrating that during the first six months of the pandemic, 52% of the hospitalized COVID-19 patients had at least one antibiotic prescription and 36% multiple antibiotics. Up to 96% of these prescriptions were given empirically, without confirmation about the bacterial infection3. A review study evaluating the number of secondary infections in COVID-19 reported that secondary bacterial or fungal infections were in approximately 8% of the patients, but the antibiotics were prescribed for 72% of the patients4. In China, even up to 99% of the patients have received antibiotics without a diagnosed bacterial co-infection5.

CRP could aid in decreasing unnecessary antibiotic prescribing in COVID-19

Antimicrobial stewardship activities have slowly integrated into clinical guidelines that have started to recommend avoidance of antibiotics for mild and moderate COVID-19 unless there is clinical suspicion of secondary bacterial infection6,7. C-reactive protein (CRP) has been reported as a potential tool to guide antibiotic prescribing in secondary bacterial infections11. In COVID-19 patients, C-reactive protein levels are commonly slightly elevated between 20-50 mg/l8-10, whereas in hospitalized patients with secondary bacterial infection, CRP is significantly higher. A German study with 99 participants reported that patients admitted to the hospital, who develop a bacterial infection, had significantly higher CRP mean on admission (130 mg/l) and during hospital stay (mean highest CRP value 293 mg/l) compared to patients who did not have secondary infection 73 and 94 mg/l, respectively11. CRP had a sensitivity of 81% and a specificity of 76% for the detection of secondary bacterial infection, and the negative predictive value was 90% in patients with CRP < 172 mg/l. Therefore, CRP could be useful especially in ruling out bacterial coinfection and in decreasing unnecessary antibiotic prescribing.

References

  1. Cong W, Poudel AN, Alhusein N et al. Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS-CoV-2 Pandemic: A Scoping Review. Antibiotics 2021; 10(6): 745.
  2. Vaughn VM, Gandhi TN, Petty LA et al. Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; 72(10): e533-e541.
  3. The PEW Charitable Trust. Could Efforts to Fight the Coronavirus Lead to Overuse of Antibiotics?, 2021.
  4. Rawson TM, Moore LSP, Zhu N et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; 71(9): 2459-2468.
  5. Cao J, Tu W-J, Cheng W et al. Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; 71(15): 748-755.
  6. National Institute for Health and Care Excellence (NICE). COVID-19 Rapid Guideline: Managing COVID-19: March 2021.
  7. World Health Organization. COVID-19 Clinical management - Living guidance, 2021.
  8. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; 395(10223): 507-513.
  9. Gao Y, Li T, Han M et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020; 92(7): 791-796.
  10. Mo P, Xing Y, Xiao Y et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020.
  11. Pink I, Raupach D, Fuge J et al. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection 2021.
Share
Facebook
Twitter
Email

Aidian Oy

Koivu-Mankkaan tie 6 B,
FI-02200 Espoo,
Finland

P.O. Box 83,
FI-02101 Espoo,
Finland

+358 10 309 3000
Company
  • About us
  • Careers
  • Contact us
  • Events
  • Product-specific inquiries
  • Sales support
  • Sales related inquiries
  • Sustainability
Products
  • Point of care
  • Microbiology
  • Molecular diagnostics
  • Hygiene monitoring
  • RIA / Collagens
  • Respiratory tract infections
Quick links
  • Aidian Academy
  • Aidian Connect
  • IFU Revision histories
Copyright © 2025 Aidian
  • Privacy Policy
  • Privacy Statements
  • Cookie Policy
  • Social Media Policy